Cargando…

Outcome of Patients With Metastatic Lung Neuroendocrine Tumors Submitted to First Line Monotherapy With Somatostatin Analogs

OBJECTIVE: Antiproliferative activity of somatostatin analogs (SSAs) has been demonstrated in digestive neuroendocrine tumors (NETs), but few data have been published in patients with pulmonary NETs. We therefore conducted a retrospective study to provide additional data on the outcome of patients w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lenotti, Elisa, Alberti, Andrea, Spada, Francesca, Amoroso, Vito, Maisonneuve, Patrick, Grisanti, Salvatore, Baggi, Alice, Bianchi, Susanna, Fazio, Nicola, Berruti, Alfredo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8111295/ https://www.ncbi.nlm.nih.gov/pubmed/33986731 http://dx.doi.org/10.3389/fendo.2021.669484

Ejemplares similares

Somatostatin Analogs Therapy in Gastroenteropancreatic Neuroendocrine Tumors: Current Aspects and New Perspectives
por: Baldelli, Roberto, et al.
Publicado: (2014)

Ovarian Strumal Carcinoid: Case Report, Systematic Literature Review and Pooled Analysis
por: Turla, Antonella, et al.
Publicado: (2022)

Endocrine and Neuroendocrine Tumors: A Special Issue
por: Berruti, Alfredo, et al.
Publicado: (2022)

Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy
por: Hu, Yuheng, et al.
Publicado: (2021)

A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy
por: Hasic Telalovic, Jasminka, et al.
Publicado: (2021)

Androgen serum levels in male patients with adrenocortical carcinoma given mitotane therapy: A single center retrospective longitudinal study
por: Delbarba, Andrea, et al.
Publicado: (2023)

Prescription patterns of somatostatin analogs in patients with acromegaly and neuroendocrine tumors
por: Machado-Alba, J. E., et al.
Publicado: (2022)

Somatostatin Receptors and Analogs in Pheochromocytoma and Paraganglioma: Old Players in a New Precision Medicine World
por: Patel, Mayank, et al.
Publicado: (2021)

THU511 Somatostatin Analogs Or Active Surveillance In Sporadic And MEN1 Associated Non-functioning Pancreatic Neuroendocrine Tumors
por: Raia, Salvatore, et al.
Publicado: (2023)

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
por: Gadelha, Mônica, et al.
Publicado: (2020)

Versatile Functions of Somatostatin and Somatostatin Receptors in the Gastrointestinal System
por: Shamsi, Bilal Haider, et al.
Publicado: (2021)

Case Report: Exceptional Response to Second Line Temozolomide Therapy in a Patient With Metastatic Adrenocortical Carcinoma
por: Cosentini, Deborah, et al.
Publicado: (2021)

Patients’ satisfaction with long-acting injectable somatostatin analog therapy for neuroendocrine tumors
por: Darden, Christina, et al.
Publicado: (2021)

Supportive therapies in patients with advanced adrenocortical carcinoma submitted to standard EDP-M regimen
por: Turla, Antonella, et al.
Publicado: (2022)

Case report: A particularly rare case of endogenous hyperinsulinemic hypoglycemia complicated with pregnancy treated with short-acting somatostatin analog injections
por: Barsi, Ádám, et al.
Publicado: (2022)

Somatostatin Analogs Treated Small Intestinal Neuroendocrine Tumor Patients Circulating MicroRNAs
por: Li, Su-Chen, et al.
Publicado: (2015)

Budget impact of somatostatin analogs as treatment for metastatic gastroenteropancreatic neuroendocrine tumors in US hospitals
por: Ortendahl, Jesse D, et al.
Publicado: (2017)

(225)Ac-Labeled Somatostatin Analogs in the Management of Neuroendocrine Tumors: From Radiochemistry to Clinic
por: Rubira, Léa, et al.
Publicado: (2023)

Synchronous AML and pancreatic neuroendocrine neoplasm, both successfully treated with somatostatin analogs and decitabine
por: Ehsanullah, Syed, et al.
Publicado: (2022)

Clinical Prognostic Factors in Patients With Metastatic Adrenocortical Carcinoma Treated With Second Line Gemcitabine Plus Capecitabine Chemotherapy
por: Grisanti, Salvatore, et al.
Publicado: (2021)

Impact of Cold Somatostatin Analog Administration on Somatostatin Receptor Imaging: A Systematic Review
por: Morland, David, et al.
Publicado: (2023)

Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs
por: Fernandes, Isabel, et al.
Publicado: (2012)

Proteomics Suggests a Role for APC-Survivin in Response to Somatostatin Analog Treatment of Neuroendocrine Tumors
por: Fotouhi, Omid, et al.
Publicado: (2016)

The Influence of Long-Acting Somatostatin Analogs on (68)Ga-DOTATATE Uptake in Patients With Neuroendocrine Tumors
por: Chahid, Youssef, et al.
Publicado: (2023)

The Spread of SARS-CoV-2 Infection Among the Medical Oncology Staff of ASST Spedali Civili of Brescia: Efficacy of Preventive Measures
por: Dalla Volta, Alberto, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Malignant Pleural Mesothelioma: A Systematic Review and Meta-Analysis
por: Gemelli, Maria, et al.
Publicado: (2022)

Combination of transsphenoidal endoscopic surgery and presurgical somatostatin analogs in thyrotropin (TSH)-secreting pituitary adenomas: Treatment outcome and long-term remission at a single pituitary center
por: Liu, Jie, et al.
Publicado: (2022)

Effects of somatostatin analogs on uptake of radiolabeled somatostatin analogs on imaging: a systematic review and meta-analysis
por: Wang, Rang, et al.
Publicado: (2023)

Novel Somatostatin Receptor Ligands Therapies for Acromegaly
por: Paragliola, Rosa Maria, et al.
Publicado: (2018)

Somatostatin receptors in congenital hyperinsulinism: Biology to bedside
por: van Albada, Mirjam E., et al.
Publicado: (2022)

A qualitative study to understand the experience of somatostatin analog treatments from the perspective of patients with neuroendocrine tumors
por: Seo, Caroline, et al.
Publicado: (2022)

Glucocorticoid Receptor Antagonism Upregulates Somatostatin Receptor Subtype 2 Expression in ACTH-Producing Neuroendocrine Tumors: New Insight Based on the Selective Glucocorticoid Receptor Modulator Relacorilant
por: Pivonello, Rosario, et al.
Publicado: (2022)

Somatostatin and Somatostatin Receptors: From Signaling to Clinical Applications in Neuroendocrine Neoplasms
por: del Olmo-Garcia, Maria Isabel, et al.
Publicado: (2021)

Role of Somatostatin Signalling in Neuroendocrine Tumours
por: Rogoza, Olesja, et al.
Publicado: (2022)

Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes
por: Bianchi, Antonio, et al.
Publicado: (2013)

Resistance to Somatostatin Analogs in Italian Acromegaly Patients: The MISS Study
por: Berton, Alessandro Maria, et al.
Publicado: (2022)

A Real-World Observational Study of the Use and Associated Costs of Treating Neuroendocrine Tumors With Somatostatin Analogs in Canada
por: Cheung, Winson Y., et al.
Publicado: (2022)

Cytotoxic Effect of Progesterone, Tamoxifen and Their Combination in Experimental Cell Models of Human Adrenocortical Cancer
por: Rossini, Elisa, et al.
Publicado: (2021)

Somatostatin-IRES-Cre Mice: Between Knockout and Wild-Type?
por: Viollet, Cécile, et al.
Publicado: (2017)

Epithelial–Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly
por: Gil, Joan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ds88k2vticfi5nr3kr1jsf1sgi